

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (Cancelled)

Claim 2 (Cancelled)

Claim 3 (Cancelled)

Claim 4 (Cancelled)

Claim 5 (Cancelled)

Claim 6 (Cancelled)

Claim 7 (Cancelled)

Claim 8 (Cancelled)

Claim 9 (Cancelled)

Claim 10 (Cancelled)

Claim 11 (Cancelled)

Claim 12 (Cancelled)

Claim 13 (Cancelled)

Claim 14 (Cancelled)

Claim 15 (Cancelled)

Claim 16 (Cancelled)

Claim 17 (Cancelled)

Claim 18 (Cancelled)

Claim 19 (Cancelled)

Claim 20 (Cancelled)

Claim 21 (Cancelled)

Claim 22 (Cancelled)

Claim 23 (Cancelled)

Claim 24 (Cancelled)

Claim 25 (Cancelled)

Claim 26 (Cancelled)

Claim 27 (Cancelled)

Claim 28 (Cancelled)

Claim 29 (Cancelled)

Claim 30 (Cancelled)

Claim 31 (Cancelled)

Claim 32 (New)      A method for changing the body temperature of a human or animal subject while controlling subject shivering, comprising:

- A)    providing a heat exchange catheter;
- B)    positioning the heat exchange catheter in the vasculature of the subject;
- C)    administering to the subject at least one drug of a type selected from the group consisting of; serotonin agonists, dopamine antagonists, dopamine agonists, sedatives, hypnotics and anxiolytics, said at least one drug being administered at a dose and by a route of administration that is effective to deter shivering during performance of the method; and
- D)    using the heat exchange catheter to transfer heat from blood flowing through the subject's vasculature.

Claim 33 (New)      A method according to claim 32 wherein Step C comprises administering a serotonin antagonist selected from the group consisting of: serotonin 5 HT1a agonists, buspirone; ipsapirone; 8-OH-DPAT and flesinoxan and pharmaceutically acceptable salts thereof.

Claim 34 (New)      A method according to claim 32 wherein Step C comprises

administering a dopamine antagonist selected from the group consisting of: haloperidol, phenothiazines, chlorpromazine, triflupromazine, thioridazine, mesoridazine, piperacetazine, piperazine, fluphenazine, trifluoperazine, acetophenazine, carphenazine, fluphenazine, perphenazine, prochlorperazine, neuroleptic dopamine antagonists, tioxanthenes, chlorprothixene, thiothixene, diphenylbutylpiperidines, pimozide, penfluridol, dibenzoxazepines, loxapine, dibenzodiazepines, clozapine, benzamides, sulpiride, butyrophenones, haloperidol, dopamine b-hydroxylase blockers, disulfiram and pharmaceutically acceptable salts thereof.

Claim 35 (New) A method according to claim 32 wherein Step C comprises administering a dopamine agonist selected from the group consisting of: amantadine, bromocriptine, piribidil, apomorphine, lisuride, pergolide, mesulergine and pharmaceutically acceptable salts thereof.

Claim 36 (New) A method according to claim 32 wherein Step C comprises administering a sedative.

Claim 37 (New) A method according to claim 32 wherein Step C comprises administering a hypnotic.

Claim 38 (New) A method according to claim 32 wherein Step C comprises administering an anxiolytic.

Claim 39. (New) A method according to claim 32 wherein the method further comprises administering to the subject at least one other drug of a type selected from the group consisting of; opioids, opioid agonists, opioid antagonists and opioid agonists/antagonists.

Claim 40. (New) A method according to claim 39 wherein the other drug comprises morphine.

Claim 41. (New) A method according to claim 39 wherein the other drug comprises an opioid agonist-antagonist selected from the group consisting of: nalorphine; pentazocine; buprenorphine; butorphanol; nalbuphine; cyclazozine; dezozine; and nalorphine; and their pharmaceutically acceptable salts thereof.

Claim 42. (New) A method according to claim 39 wherein the other drug comprises an opioid agonist selected from the group consisting of; bremazocine, nalorphine, ketazocine and alkyl ketazocines such as ethylketazocine, tifluadom, trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzene acetamide, (5a,7a,8B)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)-dec-8-yl]benzene acetamide, bremazocine hydrochloride, nalorphine hydrochloride, ketazocine salts including alkyl ketazocine methanesulfonates such as ethyl ketazocine methanesulfonate, trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzene acetamide methanesulfonate, and pharmaceutically acceptable salts thereof.

Claim 43. (New) A method according to claim 32 wherein Step C is performed before Step D.

Claim 44. (New) A method according to claim 32 wherein the heat exchange catheter provided in Step A has a heat exchanger through which a heat exchange fluid is circulated and wherein Step D comprises circulating a heat exchange fluid through said heat exchanger.

Claim 45. (New) A method according to claim 44 wherein the heat exchange fluid is circulated through the heat exchanger in a direction opposite the direction in which blood flows past the heat exchanger.